Kate Haviland

Kate Haviland, listed as senior executive, appears in our data through filings on Blueprint Medicines Corp shares, published by SEC (Form 4). Over a trading history stretching from 14 March 2017 to 17 July 2025, the count stands at 92 filings.

Market trades split into 1 purchase (€49k) and 57 sales (€11.4M). The net balance comes to €11.4M on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 7 share grants and 27 option exercises. In 2025 alone, the filings show no purchases and 3 sales.

On 21 July 2025 came the latest disclosure, a share grant in Blueprint Medicines Corp. The clock since the last published purchase (7 November 2022) now reads 1,447 days. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.